GSK in Talks to Buy Nuvalent for More Than $9 Billion: FT (opens original article in a new tab)

GSK Plc is in talks to acquire Nuvalent Inc. for between $9 billion and $10 billion, according to the Financial Times.

• GSK is discussing a purchase of Nuvalent Inc.
• The reported price range is $9 billion to $10 billion.
• The source of the information is the Financial Times, citing unidentified individuals.